Edwards Lifesciences has received CE Mark approval for expanding the use of the Sapien 3 transcatheter heart valve to patients with severe, symptomatic aortic stenosis at intermediate risk for ...

A Japanese center found that hemolysis was significantly more common after TAVR with the Sapien 3 Ultra Resilia than with its predecessor device, despite the improvement on paravalvular leaks. Annular ...

Edwards Lifesciences Corporation EW recently announced FDA approval for expanding the use of its flagship SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valve systems to treat severe, symptomatic ...

(UPDATED) CHICAGO, IL—The latest iteration of the FDA-approved balloon-expandable transcatheter aortic valve has proven itself superior to surgery among intermediate-risk patients in a ...

Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...

NEWBURY, May 8 2024 -- Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough ...

The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (“TPV”) system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with extreme pulmonary ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...